Personal neoantigen–based cancer vaccines are designed to target antigens arising from
tumor-specific mutations within individual cancers and present a tremendous opportunity to …

Neoantigens are tumor-specific proteins and peptides that can be highly immunogenic.
Immune-mediated tumor rejection is strongly associated with cytotoxic responses to …

Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations
arising in each patient's tumor are breathing new life into a struggling approach. Data …

Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

Cancer immunotherapy has achieved multiple clinical benefits and has become an
indispensable component of cancer treatment. Targeting tumor-specific antigens, also …

The process of tumorigenesis leaves a series of indelible genetic changes in tumor cells,
that when expressed, have the potential to be tumor-specific immune targets. Neoantigen …

Although significant advances in immunotherapy have revolutionized the treatment of many
cancer types over the past decade, the field of vaccine therapy, an important component of …

During their development and progression tumors acquire numerous mutations that, when
translated into proteins give rise to neoantigens that can be recognized by T cells. Initially …

Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer
vaccines with the routine ability to limit or eliminate tumor growth in humans have been …

Neoantigen cancer vaccines harbor promise as next-generation immuno-oncology
therapies, whereby cancer vaccines are tailored to the patient's tumor antigen and represent …